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Abstract
An association between protein glycosylation and tumorigenesis has been recognized for over
10 years. Associations linking the importance of glycosylation events to tumor biology, especially
the progression to metastatic disease, have been noted over many years, Recently, a mouse
model in which b1,6-N-acetylglucosaminyltransferase V (a rate-limiting enzyme in the N-glycan
pathway) has been knocked out, was used to demonstrate the importance of glycosylation in
tumor progression. By crossing mice lacking this enzyme with a transgenic mouse model of
metastatic breast cancer, metastatic progression of the disease was dramatically reduced.
These experiments provide in vivo evidence for the role of N-linked glycosylation in metastatic
breast cancer and have significant implications for the development of new treatment strategies.
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The progression of breast cancer to a metastatic, hormone-
refractory stage heralds a poor prognosis, with less than
5% of patients having a long-term, complete response to
treatment [1]. The cancer cell has to overcome many levels
of regulation that maintain normal cellular growth for breast
cancer to evolve to this advanced state. Multiple genetic
alterations that enable the cancer cell to become self-suffi-
cient (reviewed in [2]) in the production of growth signals
have accumulated, such as the overexpression of myc (for
a review, see [3]) and her2/neu [4], as well as losing the
inhibitory effects of tumor suppressor genes such as p53
and Rb (reviewed in [5]). It is also clear that the normal pro-
tective apoptotic response to genomic damage is sup-
pressed through the expression of survival factors, allowing
such cells to accumulate and undergo further genetic aber-
ration. The reactivation of telomerase also ensures that
tumor cells have limitless replicative potential [6]. However,
it is the ability of cancer cells to spread to remote locations
and grow without restraint that kills the patient. The
metastatic spread of breast cancer involves the ability of
the cancer cells to escape their normal tissue boundaries
through invasion, engraftment and their ability to recruit a
vascular supply (for a review, see [7]). Tissue invasion and
metastasis are highly dependent on alterations in the extra-
cellular matrix [8] and cell–cell interactions that, in part,
involve structural changes in cell surface components,
including glycosylation (for a review, see [9]). In the work of
Granovsky et al, the importance of specific glycosylation
events in mammary cancer metastases has been clearly
demonstrated  in vivo using genetically altered mice [10].Breast Cancer Research    Vol 2 No 5 Couldrey and Green
The N-linked glycoproteins have been shown to have impor-
tant roles in cell–cell interactions including fertilization,
inflammation, development and differentiation. These mole-
cules are composed of a polypeptide backbone glycosy-
lated in the endoplasmic reticulum with one or more
carbohydrate chains through asparagine residues. The addi-
tion of the carbohydrate moiety occurs en bloc and, initially,
the oligosaccharide chains of all glycoproteins are identical.
Numerous Golgi enzymes (an estimated > 200 glucosi-
dases, mannosidases, N-acetylglucosamine [GlcNAc], and
Gal transferases) are important in modifying glycoproteins
to produce a diverse array of branching oligosaccharides.
One subgroup composed of six Golgi enzymes is the
N-acetylglucosamininyltransferases. The relation of
Golgi  b1,6-N-acetylglucosaminyltransferase V (MGAT5;
EC2.4.1.155) to tumorigenesis has been the focus of
several recent studies (as reviewed in [9]). This enzyme
catalyzes the addition of 1,6-GlcNAc to form tri- and tetra-
antenna-like oligosaccharides [11]. Products of this reaction
are often modified further to form polyactosamines.
Malignant transformation has been associated with
changes in the glycosylation of cell surface proteins. For
example, the N-linked oligosaccharides containing the
GlcNAcb1,6Man branch are increased after transformation
in many cell types by a number of tumor viruses and onco-
genes that induce the expression of MGAT5 [12]. Cells
infected with MGAT5 express increased GlcNAcb1,6Man
on integrins aI, aV and b1 associated with increased cellu-
lar motility and decreased substratum adhesion [13].
Increased amounts of Mgat5 glycan products have also
been reported in malignant tissue in vivo, and correlate
with disease progression [12,14–20].
By generating mice with mutant alleles of Mgat5 by homol-
ogous recombination in embryonic stem cells, Granovsky
et al were able to study the phenotypic effects produced
by the absence of Mgat5 on both normal development and
metastatic growth of mammary cancer. It has been
demonstrated that while Mgat5 is not essential for devel-
opment, it plays a critical role in metastatic progression of
mammary tumors in the MMTV-polyoma middle-T (PyMT)
transgenic mouse model [20].
The PyMT mouse model consistently develops mammary
tumors with a high incidence of associated lung meta-
stases. No differences in the occurrence of very early
mammary lesions were observed when PyMT transgenic
mice carrying either the Mgat5+/+, Mgat5+/–, or Mgat5–/–
genotype were analyzed; thus, the absence of Mgat5 did
not appear to affect the initiation of early events involved in
the PyMT-induced oncogenesis. However, once initiated,
the rates of mammary tumor growth and metastases
observed in PyMT-Mgat5–/– mice were considerably less
than the rates in PyMT transgenic littermates expressing
Mgat5. Northern analysis demonstrated that the decrease
in tumor growth was not a secondary effect due to
reduced transgene expression since steady state levels of
the oncogene were not changed in the absence of one or
both MGAT5 alleles. Significantly, the incidence of lung
metastases in PyMT-Mgat5–/– mice was approximately 5%
of that seen in PyMT-Mgat5+/– and PyMT-Mgat5+/+ mice.
Since the design of the mutant Mgat5 construct leads to
the expression of lacZ under the control of the endoge-
nous Mgat5 regulatory sequences, the results also
demonstrate that PyMT is a positive regulator of Mgat5
expression.
The authors explore two potentially related mechanisms of
Mgat5 action by which 1,6-GlcNAc glycosylation may be
involved in the metastatic phenotype. First, how this spe-
cific glycosylation may lead to alterations in interactions
with adhesion proteins, cellular structure and cell–cell
interactions. The second mechanism is the role by which
Mgat5 may affect intracellular signaling activated by PyMT,
and thus accelerate cell growth. PyMT-Mgat5+/– tumor
cells exhibited impaired membrane ruffling compared with
that of PyMT-Mgat5+/+ cells. This appears to be due to an
inhibition of PI3 kinase activation through the PyMT-c-Src
pathway, leading to reduced phosphorylation of paxillin
and its recruitment into focal adhesions. The authors con-
clude that the intrinsic defect in cells lacking Mgat5 is the
inability to accelerate focal adhesion turnover and signal-
ing through PI3 kinase/PKB by PyMT.
The precise location of the MGAT5 products on specific
glycoprotein(s) and their role in regulating tumor growth
and metastasis currently remains to be determined.
Further work localizing MGAT5 products may lead to the
identification of specific cell surface molecules that may
be targets for inhibiting tumor development and metas-
tases. Given the universal nature of glycosylation, deter-
mining specificity is important so as not to disrupt other,
potentially important cellular functions. The abnormal phe-
notypes seen in adult Mgat5–/– animals, including abnor-
mal inflammatory responses, glomeruli and nurturing
behavior, illustrate this point. Experiments in which another
glycosylation enzyme, Mgat1, was knocked out in mice led
to embryonic lethality [21]. However, Mgat1 regulates
early glycosylation events and presumably affects a larger
array of glycosylated glycoproteins, which may account for
why this enzyme is essential for embryonic development.
The article by Granovsky et al clearly illustrates the role of
MGAT5 in tumor progression. However, the signal-trans-
duction pathway through which PyMT induces tumor for-
mation is different from other oncogene pathways that
lead to cellular transformation. For instance, breast cancer
is associated with the overexpression of several onco-
genes including myc [3] and her2/neu [4], and with the
loss of function of tumor suppressor genes such as p53,
Rb [5], BRCA1 [22] and BRCA2 [23]. Since Mgat5http://breast-cancer-research.com/content/2/5/321
affects a particular part of the PyMT signaling pathway, a
number of interesting questions remain in relation to how
the absence of Mgat5 may influence the metastatic poten-
tial of tumors induced through other pathways. It will be
interesting to determine whether crosses between
Mgat5–/– and other transgenic mammary cancer models
will similarly alter the metastatic phenotype. There are,
unfortunately, currently few useful mammary cancer
models in genetically engineered mice that develop a high
rate of metastases. There are presently also no good
transgenic models in which to study mammary metastases
to the bone, liver or to the brain, organs that are frequently
the sites of metastases in human breast cancer.
Interestingly, a small percentage of PyMT Mgat5–/– tumors
acquired a fast-growth phenotype similar to that of PyMT
Mgat5+/+ tumors that was not the result of 1,6-GlcNAc
glycosylation. This indicates that while Mgat5 plays an
important role in metastatic growth, tumor cells may acti-
vate other mechanisms that lead to aggressive, metastatic
growth even in the absence of Mgat5 activity. Since glyco-
sylation events occur within the Golgi in the cell, it remains
unclear whether therapeutic targets to inhibit Mgat5 gly-
cosylation will be efficacious if delivered to the extracellu-
lar environment or will require transport or expression
within the cell.
These findings underscore the importance of glycosylation
events in tumor biology, and have significant implications
for understanding and treating malignant disease. While
additional mechanisms involved in metastatic progression
will undoubtedly be identified in the future, perhaps
inhibitors of specific glycosylation enzymes will prove to
be useful in halting tumor progression and metastasis.
Additional studies on the relationship between glycosyla-
tion and metastases should provide important insights into
mechanisms of cell–cell interactions and tumor progres-
sion to the metastatic stage.
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